About Us

BioLeap is an emerging drug discovery company enabled by the next generation of computational fragment-based design technology. BioLeap's design platform quickly predicts binding affinity based on thermodynamic principles giving drug designers new insights to efficiently create non-obvious molecules and improve existing molecules. Lack of chemical diversity has blocked the progress of many high-priority targets during the lead identification and lead optimization phase for failure to provide either a suitable chemical starting point or a replacement structural class to a doomed lead series. BioLeap's technology provides a viable alternative to high-throughput screening and traditional shape-based âœdockingâ approaches. BioLeap has identified lead compounds in four collaborative ventures and is seeking new partners who are interested in exploiting its compelling compound design and engineering platform.


Business size

1-10 employees


Commercial presence